❮ Back to Researchers

Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Email: Lawrence.Leiter@unityhealth.to
Tel: 416-867-7441

Research Programs

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 750 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher

Dr. Leiter is a past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Distinguished Service Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.  In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences

Recent Publications

  1. Krychtiuk, KA, Marquis-Gravel, G, Murphy, S, Chiswell, K, Green, JB, Leiter, LA et al.. Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease - insights from the Harmony Outcomes trial. Eur J Prev Cardiol. 2024; :. doi: 10.1093/eurjpc/zwae379. PubMed PMID:39602568 .
  2. Mancini, GBJ, Pearson, GJ, Barry, AR, Couture, P, Dayan, N, Francis, GA et al.. Prevention and Management of Cardiovascular Disease in Primary Care: A Comment on the PEER Simplified Lipid Guideline. CJC Open. 2024;6 (10):1189-1198. doi: 10.1016/j.cjco.2024.06.006. PubMed PMID:39525338 PubMed Central PMC11544166.
  3. Yang, S, Back, S, Grant, SM, Ayoub-Charette, S, Chen, V, Lin, EJ et al.. Effects of Extracted Pulse Proteins on Lipid Targets for Cardiovascular Risk Reduction: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2024;16 (21):. doi: 10.3390/nu16213765. PubMed PMID:39519598 PubMed Central PMC11548137.
  4. Leiter, LA, Hegele, RA, Brown, V, Bergeron, J, Mackinnon, ES, Mancini, GBJ et al.. Erratum: Leiter et al. Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Reviews in Cardiovascular Medicine. 2024; 25: 190. Rev Cardiovasc Med. 2024;25 (10):383. doi: 10.31083/j.rcm2510383. PubMed PMID:39484145 PubMed Central PMC11522857.
  5. Klonoff, DC, Freckmann, G, Pleus, S, Kovatchev, BP, Kerr, D, Tse, CC et al.. The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors. J Diabetes Sci Technol. 2024;18 (6):1346-1361. doi: 10.1177/19322968241275701. PubMed PMID:39369312 PubMed Central PMC11531029.
  6. Bhatt, AS, Bhatt, DL, Steg, PG, Szarek, M, Cannon, CP, Leiter, LA et al.. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF. J Am Coll Cardiol. 2024;84 (12):1078-1088. doi: 10.1016/j.jacc.2024.06.036. PubMed PMID:39260929 .
  7. Erlich, MN, Ghidanac, D, Blanco Mejia, S, Khan, TA, Chiavaroli, L, Zurbau, A et al.. A systematic review and meta-analysis of randomized trials of substituting soymilk for cow's milk and intermediate cardiometabolic outcomes: understanding the impact of dairy alternatives in the transition to plant-based diets on cardiometabolic health. BMC Med. 2024;22 (1):336. doi: 10.1186/s12916-024-03524-7. PubMed PMID:39169353 PubMed Central PMC11340166.
  8. Wright, RS, Ray, KK, Landmesser, U, Koenig, W, Raal, FJ, Leiter, LA et al.. Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease: A Pooled Analysis of the ORION-10 and ORION-11 Randomized Trials. Mayo Clin Proc. 2024; :. doi: 10.1016/j.mayocp.2024.03.025. PubMed PMID:39093262 .
  9. Leiter, LA, Hegele, RA, Brown, V, Bergeron, J, Mackinnon, ES, Mancini, GBJ et al.. Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Rev Cardiovasc Med. 2024;25 (5):190. doi: 10.31083/j.rcm2505190. PubMed PMID:39076473 PubMed Central PMC11267205.
  10. Moura, FA, Bellavia, A, Berg, DD, Melloni, GEM, Feinberg, MW, Leiter, LA et al.. Risk of new-onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes Obes Metab. 2024;26 (10):4441-4449. doi: 10.1111/dom.15798. PubMed PMID:39056220 PubMed Central PMC11410501.
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto